Question to the HM Treasury:

To ask the Chancellor of the Exchequer, whether she plans to review the operation of the merged R&D tax relief scheme in relation to companies providing pre-clinical research services.

The Government recognises the important role that life sciences research and development (R&D) plays in driving innovation and economic growth as well as the benefits it can bring for society. The Government committed to maintaining the generosity of the rates in both the merged R&D Expenditure Credit (RDEC) scheme and the Enhanced R&D Intensive Support (ERIS). This, combined with the commitment to cap the headline rate of Corporation Tax, means that companies doing qualifying R&D – including pre-clinical R&D – will continue to receive between £15 to £27 for every £100 spent on R&D.

Under the merged R&D scheme, relief is generally available to the company that decides to undertake R&D and bears the financial risk, rather than the company contracted to carry it out, subject to limited exceptions. This approach is intended to ensure support is targeted at the company that invests in the R&D. These rules apply to pre-clinical research services in the same way as they do for all other companies.